NO961995L - Anvendelse av IGF-BP for renaturering av IGF - Google Patents

Anvendelse av IGF-BP for renaturering av IGF

Info

Publication number
NO961995L
NO961995L NO961995A NO961995A NO961995L NO 961995 L NO961995 L NO 961995L NO 961995 A NO961995 A NO 961995A NO 961995 A NO961995 A NO 961995A NO 961995 L NO961995 L NO 961995L
Authority
NO
Norway
Prior art keywords
igf
insulin
growth factor
renaturation
binding protein
Prior art date
Application number
NO961995A
Other languages
English (en)
Other versions
NO961995D0 (no
Inventor
Bjorn Nilsson
Sophia Elisabeth Hober
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of NO961995L publication Critical patent/NO961995L/no
Publication of NO961995D0 publication Critical patent/NO961995D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anvendelse av insulinlignende vekstfaktorbindingsprotein (IGF-BP) for refolding av insulinlignende vekst- faktor (IGF). Bindingsproteinet er for- trinnsvis hvilken som helst av IGF-BP- 1, IGF-BP-2, IGF-BP-3, IGF-BP-4, IGF- BP-5 eller IGF-BP-6 og den insulin- lignende vekstfaktoren er fortrinnsvis IGF-I. En fremgangsmåte for fremstil- ling av biologisk aktiv, nativ IGF-I eller IGF-II, kjennetegnet ved at IGF-I eller IGF-II i redusert eller misfoldet utgave behandles med IGF-BP, er også besrekvet.
NO961995A 1993-11-16 1996-05-15 Anvendelse av IGF-BP for renaturering av IGF NO961995D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9303784A SE9303784D0 (sv) 1993-11-16 1993-11-16 Igf
PCT/SE1994/001076 WO1995014034A1 (en) 1993-11-16 1994-11-14 Use of igf-bp for refolding of igf

Publications (2)

Publication Number Publication Date
NO961995L true NO961995L (no) 1996-05-15
NO961995D0 NO961995D0 (no) 1996-05-15

Family

ID=20391767

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961995A NO961995D0 (no) 1993-11-16 1996-05-15 Anvendelse av IGF-BP for renaturering av IGF

Country Status (12)

Country Link
US (1) US5683980A (no)
EP (1) EP0736040B1 (no)
JP (1) JP3609410B2 (no)
AT (1) ATE190627T1 (no)
AU (1) AU684117B2 (no)
CA (1) CA2176599A1 (no)
DE (1) DE69423516T2 (no)
FI (1) FI962081A7 (no)
NO (1) NO961995D0 (no)
NZ (1) NZ276520A (no)
SE (1) SE9303784D0 (no)
WO (1) WO1995014034A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789547A (en) * 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
JP3734634B2 (ja) * 1999-03-03 2006-01-11 ヒゲタ醤油株式会社 タンパク質の活性化方法及び該装置
KR20020074749A (ko) * 2001-03-21 2002-10-04 한국생명공학연구원 재조합 인슐린 유사성장인자-1의 대량 생산방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
WO1992014834A1 (en) * 1991-02-14 1992-09-03 The Whittier Institute For Diabetes And Endocrinology Insulin-like growth factor binding protein
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
WO1993019084A1 (en) * 1992-03-24 1993-09-30 Synergen, Inc. Refolding and purification of insulin-like growth factor i
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury

Also Published As

Publication number Publication date
JP3609410B2 (ja) 2005-01-12
US5683980A (en) 1997-11-04
AU1080895A (en) 1995-06-06
ATE190627T1 (de) 2000-04-15
EP0736040A1 (en) 1996-10-09
NO961995D0 (no) 1996-05-15
DE69423516D1 (de) 2000-04-20
FI962081L (fi) 1996-07-15
EP0736040B1 (en) 2000-03-15
JPH09505077A (ja) 1997-05-20
CA2176599A1 (en) 1995-05-26
SE9303784D0 (sv) 1993-11-16
FI962081A0 (fi) 1996-05-15
NZ276520A (en) 1997-11-24
DE69423516T2 (de) 2000-09-14
WO1995014034A1 (en) 1995-05-26
AU684117B2 (en) 1997-12-04
FI962081A7 (fi) 1996-07-15

Similar Documents

Publication Publication Date Title
CA2030518A1 (en) Osteoinductive compositions
DK1100529T4 (da) Thymosin beta 4 fremmer sårheling
ATE219685T1 (de) Zusammensetzungen enthaltend eine kombination von knochenmorphogenetischem protein und parathyroid- ähnlichem peptid
MX9604635A (es) Tratamiento del sindrome de insensibilidad parcial a la hormona del crecimiento.
FR2678624B1 (no)
DE3852116D1 (de) Herstellung von Proteinen in aktiver Form.
EP0429586A4 (en) Growth hormone fusion proteins
ATE150648T1 (de) Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)
ATE125268T1 (de) Säureempfindliche subeinheit eines insulinähnlichen wachstumfaktors-bindeprotein- komplexes.
DK0661990T3 (da) Fremgangsmåde til systemisk behandling af kataboliske tilstande og systemisk vævsbeskadigelse
DE69523611D1 (de) Neues verfahren für die produktion von biologisch aktivem protein (tgf)
NO961995L (no) Anvendelse av IGF-BP for renaturering av IGF
ATE207933T1 (de) Verfahren zur herstellung vom aktieven protein dimerischen
ATE121296T1 (de) Igf-i zur behandlung von nebeneffekten der steroidtherapie.
ATE243712T1 (de) Vekürztes insulinähnlichen wachstumsfaktor- bindendes protein mit mitogener aktivität
ATE192656T1 (de) Verfahren zur behandlung von patienten mit chronischer lebererkrankung
DK162880C (da) Fremgangsmaade til behandling af acycli hos faar og kvaeg, og anvendelse af gestagener og lh-rh eller dettes analoge ved behandling af acycli hos faar og kvaeg
ATE261985T1 (de) Verfahren zur herstellung von richtig gefaltetem, biologisch aktivem, rekombinantem protein
SE9303068D0 (sv) New use
DE69126180D1 (de) Behandlung polyzystischer ovarkrankheit
SE9002731D0 (sv) Product comprising growth factor
DK194990D0 (da) Aldc-derivat og anvendelse deraf
GR3025246T3 (en) METHOD FOR PREPARING A PROTEIN SELECTED FROM THE CYTOKINE GROUP, COMPRISING AT LEAST ONE INTRAMOLECULAR DISULPHIDE BOND BY OXIDATION, AT A pH OF LESS THAN 5.0, OF THE REDUCED RECOMBINANT PROTEIN
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
MX9710291A (es) Inhibidores ligantes de proteinas de fijacion con factor de crecimiento del tipo de insulina y metodos de uso para los mismos.